⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OSTX News
OS Therapies Incorporated
Form 8-K
sec.gov
OSTX
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program Ready to Announce with Confidence?
newsfilecorp.com
OSTX
Form 8-K/A
sec.gov
OSTX
OS Therapies Third Quarter 2026 Corporate Outlook Ready to Announce with Confidence?
newsfilecorp.com
OSTX
Form 8-K
sec.gov
OSTX
OS Therapies Appoints Dr. Craig Eagle to Board of Directors Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Provides U.S. Regulatory Update Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma Ready to Announce with Confidence?
newsfilecorp.com
OSTX